image credit: Adobe Stock

China-Developed mRNA Covid Vaccine Starts Test Production

January 6, 2023

Chinese drugmaker CanSino Biologics Inc. started trial production of a vaccine targeting new variants of Covid-19 that are behind the country’s current outbreak, which would be among the first developed in China using the mRNA technology that drove inoculation in the U.S. and other countries.

The Tianjin-based biotech firm plans to produce 100 million doses of the vaccine, designed to combat Omicron during the first phase of manufacturing, according to a company release posted to its social-media account late on Thursday.

Read More on The Wall Street Journal